Fri, Nov 22, 2024
Volume 11, Issue 2 (Mar-Apr 2017)
mljgoums 2017, 11(2): 1-4 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taherizadeh M, Khoshnia M, Shams S, Joshaghani H. Comparison of Plasma Taurine Levels between Patients with Esophageal Cancer and Healthy Controls. mljgoums 2017; 11 (2) :1-4
URL: http://mlj.goums.ac.ir/article-1-975-en.html
URL: http://mlj.goums.ac.ir/article-1-975-en.html
1- Golestan University of Medical Sciences , taherizadeh.mahsa@yahoo.com
2- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3- Children Medical Center, Tehran University of Medical Sciences, Tehran, Iran
2- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3- Children Medical Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (9418 Views)
ABSTRACT
Background and Objectives: The incidence rate of esophageal cancer (EC) is high in north and northeast of Iran. Taurine is a sulfur-containing amino acid with a wide range of vital biological functions. The aim of this study was to compare plasma levels of taurine between patients with EC and healthy controls.
Methods: Plasma samples from 36 recently diagnosed cases of EC and 36 healthy adults were analyzed by high-pressure liquid chromatography. Data analysis was done using SPSS (version 16). The t-test was used to evaluate significant differences in the level of taurine between the two groups. P-values less than 0.05 were considered statistically significant.
Results: Patients with EC had significantly higher levels of plasma taurine compared with the controls (P<0.05).
Conclusion: Patients with EC have significantly higher levels of plasma taurine compared with healthy individuals. This finding suggests that the measurement of plasma taurine in patients with EC could be useful for the early diagnosis of the disease.
Keywords: Esophageal Cancer, Taurine, HPLC.
Background and Objectives: The incidence rate of esophageal cancer (EC) is high in north and northeast of Iran. Taurine is a sulfur-containing amino acid with a wide range of vital biological functions. The aim of this study was to compare plasma levels of taurine between patients with EC and healthy controls.
Methods: Plasma samples from 36 recently diagnosed cases of EC and 36 healthy adults were analyzed by high-pressure liquid chromatography. Data analysis was done using SPSS (version 16). The t-test was used to evaluate significant differences in the level of taurine between the two groups. P-values less than 0.05 were considered statistically significant.
Results: Patients with EC had significantly higher levels of plasma taurine compared with the controls (P<0.05).
Conclusion: Patients with EC have significantly higher levels of plasma taurine compared with healthy individuals. This finding suggests that the measurement of plasma taurine in patients with EC could be useful for the early diagnosis of the disease.
Keywords: Esophageal Cancer, Taurine, HPLC.
Research Article: Original Paper |
Received: 2017/08/2 | Accepted: 2017/08/2 | Published: 2017/08/2 | ePublished: 2017/08/2
Received: 2017/08/2 | Accepted: 2017/08/2 | Published: 2017/08/2 | ePublished: 2017/08/2
References
1. Islami F KF, Nasrollahzadeh D, Aghcheli K,Sotoudeh M, Abedi-Ardekani B, et al. Socio-economic status and oesophageal cancer: results from a populationbased case-control study in a high-risk area. Int J Epidemiol. 2009; 38(23): 978-88. doi: 10.1093/ije/dyp195. [DOI:10.1093/ije/dyp195]
2. Kamangar F MR, Dawsey SM, Saidi F. Esophageal cancer in northeastern Iran: a review. Arch Iran Med. 2007; 10(4): 70-82.
3. Ghavamzadeh A MA, Jahani M, Rastegarpanah M, Iravani M. Esophageal cancer in Iran. Semin Oncol. 2001; 28(2): 153-7. [DOI:10.1016/S0093-7754(01)90086-7]
4. Huxitable R. Physiological action of taurine. Physiol Rev. 1992; 72(1): 101-63. [DOI:10.1152/physrev.1992.72.1.101]
5. El-Agousa I E-nD, Eissa S, Sharoud M. Possible ameliorative effect of antioxidant (Taurine) in pregnant toxemic female Rats. Open Hypertention J. 2009; 2: 1-15. [DOI:10.2174/1876526200902010001]
6. Schuller-Levis GB PE. Taurine: new implications for an old amino acid. FEMS Microbiol Lett. 2003; 226: 195-202. [DOI:10.1016/S0378-1097(03)00611-6]
7. Abe M TM, Takeuchi K, Fukuda M. Studies on the significance of taurine in radiation injury. Radiat Res. 1968; 33: 563-73. [DOI:10.2307/3572413]
8. Gray GE LA, Meguid MM. Taurine-supplemented total parenteral nutrition and taurine status of malnourished cancer patients. Nutrition. 1994; 10(1): 11-5.
9. Vinton NE LS, Ament ME, Kopple JD. Taurine concentrations in plasma and blood cells of patients undergoing long-term parenteral nutrition. Am J Clin Nutr. 1986; 44: 398-404.
10. Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Mönnighoff I, Buchczyk D, et al. Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J. 2006; 20(3): 574-6. [DOI:10.1096/fj.05-5016fje]
11. Reddy BS, Rao CV, Rivenson A, Kelloff G. Chemoprevention of colon carcinogenesis by organosulfur compoubds. Cancer Res. 1993; 53(15): 3493-8.
12. Cheng K, Xie G, Raufman JP. Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol. 2007; 73(7): 1001-12. [DOI:10.1016/j.bcp.2006.11.028]
13. Monoson J RP, Donohue J. Taurolidine inhibits tumor necrosis factor (TNF) toxicity - New evidence of TNF and endotoxin synergy. Eur J Surg Oncol. 1993; 19(3): 226-31.
14. Jacobi C MC, Braumann C. Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 2005; 16(9): 917-21. [DOI:10.1097/01.cad.0000176502.40810.b0]
15. Rodak R KH, Ishihara H. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005; 102(6): 1055-68. [DOI:10.3171/jns.2005.102.6.1055]
16. Turnell D, Cooper J. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clinical Chemistry. 1982; 28(3): 527-31.
17. Aledavood A1 AK, Sabouri G1. Esophageal Cancer in Northeast of Iran. Iran J Cancer Prev. 2011; 4(3): 125-9.
18. Zacarias-Castillo RR H-RA, Zajarias-Rabchinskey A, González-Bárcenad D. Hiperhomocisteinemia. Um nuevo factor de riesgo coronariano. Gac Med Mex. 2001; 137(4): 335-45.
19. Ishigami T FT, Simbula G. Regulatory effects of senescence marker protein 30 on the proliferation of hepatocytes. Pathol Int. 2001; 51(7): 491-7. [DOI:10.1046/j.1440-1827.2001.01238.x]
20. El-Idrissi D MK, Belgacem S. Constraints and obstacles to social health protection in the Maghreb: the cases of Algeria and Morocco. Bull World Health Organ. 2008; 86: 902-4. [DOI:10.2471/BLT.08.053736]
21. Folkman J KR. Tumor Angiogenesis. In Kufe DW, Bast RC, Hart WN, et al. (Holland-Feri. Cancer Medicin) 6th Ed by BC Decker Inc Hamolton, London. 2003:161-94.
22. Folkman J KR. Tumor Angiogenesis. In Kufe DW, Bast RC, Hart WN, et al. (Holland-Feri. Cancer Medicin). On line 7th Ed by BC Decker Inc Hamolton, London. 2006:161-94.
23. Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, et al. Phase I study of tauromustine administered in a weekly schedule. Eur J Cancer. 1993; 29(13): 1901-2. [DOI:10.1016/0959-8049(93)90547-S]
24. Singh G GH, Milsom JW, Chaudry IH. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors. Dis Colon Rectum. 1993; 36(4): 394-9. [DOI:10.1007/BF02053946]
25. Bibby M LP, Al-Ghabban A, Double J. Influence of hydralazine on the pharmacokinetics of taurmustine in mice-. Br J Cancer Biochem Biophys. 1992; 65(3): 347-50.
26. Tabassum H PS, Rehman H, Dev Banerjee B, Siemen D, Raisuddin S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum Exp Toxicol. 2007; 26(6): 509-18. [DOI:10.1177/0960327107072392]
27. Lamonica-garcia V MF LM MF, Henry M, Burini R. Plasma taurine levels in patients with esophagus cancer. Arq Gastroenterol. 2008; 45(3): 199-203.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.